NEK5

Serine/threonine-protein kinase Nek5 · Q6P3R8 · NEK5 on Sugi Atlas →

1,698 patent compounds predicted against NEK5, 1,546 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gsk-461364 (SCHEMBL310080)	1.00	1/20
SCHEMBL1128220	1.00	1/20
SCHEMBL1992841	1.00	1/20
SCHEMBL3995502	1.00	1/20
Gsk-461364 (SCHEMBL4276841)	1.00	1/20
SCHEMBL2973906	0.88	1/20
SCHEMBL1128513	0.86	1/20
SCHEMBL2973537	0.86	1/20
SCHEMBL4405982	0.86	1/20
SCHEMBL4562944	0.86	1/20
SCHEMBL1128074	0.85	1/20
Hydrochloric Acid (SCHEMBL3107975)	0.85	1/20
Hydrochloric Acid (SCHEMBL3111856)	0.85	1/20
SCHEMBL4410441	0.85	1/20
Hydrochloric Acid (SCHEMBL4398123)	0.83	1/20
Hydrochloric Acid (SCHEMBL4541913)	0.83	1/20
SCHEMBL1128065	0.81	1/20
SCHEMBL1128216	0.81	1/20
SCHEMBL1128228	0.81	1/20
Trimethylammonium (SCHEMBL1128252)	0.81	1/20

Clinical trials — most relevant to NEK5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Deucravacitinib Rosacea	PHASE2	WITHDRAWN
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients	PHASE1/PHASE2	COMPLETED
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Gene Therapy for Netherton Syndrome	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Cyclosporin A Therapy in Childhood Nephrotic Syndrome	nan	UNKNOWN
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm	nan	UNKNOWN
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice	nan	ACTIVE_NOT_RECRUITING
Hereditary Tubulointerstitial Nephritis	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Study of Adrenal Gland Tumors	nan	COMPLETED
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease	nan	RECRUITING
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue	nan	RECRUITING
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue	nan	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NEK5 binder may also engage these)

Protein	Name	Similarity
F1M5M3	—	0.995	F1M5M3 →
Q9R0A5	—	0.993	Q9R0A5 →
A7MBB4	—	0.992	A7MBB4 →
P51954	—	0.992	P51954 →
Q9Z1J2	—	0.992	Q9Z1J2 →
NEK4	Serine/threonine-protein kinase Nek4	0.991	landscape →
Q5SW75	—	0.991	Q5SW75 →
Q8C0P0	—	0.991	Q8C0P0 →
Q28DE6	—	0.990	Q28DE6 →
A2ARZ3	—	0.990	A2ARZ3 →
Q3UIZ8	—	0.990	Q3UIZ8 →
O88196	—	0.989	O88196 →
WNK3	Serine/threonine-protein kinase WNK3	0.989	landscape →
Q9LHI7	—	0.989	Q9LHI7 →
Q6NTJ3	—	0.989	Q6NTJ3 →
P01103	—	0.989	P01103 →
Q8BZ21	—	0.989	Q8BZ21 →
Q3UTQ8	—	0.988	Q3UTQ8 →
Q5ZJK5	—	0.988	Q5ZJK5 →
P23497	—	0.988	P23497 →
P52730	—	0.988	P52730 →
E9PVB5	—	0.988	E9PVB5 →
Q9UHV7	—	0.988	Q9UHV7 →
Q8VDU5	—	0.988	Q8VDU5 →
Q6YY75	—	0.988	Q6YY75 →
F1MJR8	—	0.987	F1MJR8 →
Q5T7B8	—	0.987	Q5T7B8 →
Q8BMD7	—	0.987	Q8BMD7 →
Q14BK3	—	0.987	Q14BK3 →
Q949U2	—	0.987	Q949U2 →